General description
An antibiotic that acts as a potent inhibitor of HMG-CoA reductase, thus suppresses Ras farnesylation. Inhibitor of myoblast fusion. Causes cell cycle arrest in late G1 phase. May induce bone morphogenic protein-2 (BMP-2). This product requires activation for use in cell culture and cell-free assay systems. To activate, treat with ethanol solution with 1 N NaOH and then neutralize with 1 N HCl to pH 7.2 (see Keyomarsi, K . et al. 1991).
An antibiotic that acts as a potent inhibitor of HMG-CoA reductase, thus suppressing Ras farnesylation. Inhibitor of myoblast fusion. Also may induce bone morphogenic protein-2 (BMP-2). Causes cell cycle arrest in late G1 phase.
This is an inactive form which may require activation for use with isolated cells depending upon the application. To activate, treat with NaOH in ethanol and then neutralize to pH 7.2.
Biochem/physiol Actions
Cell permeable: no
Primary Target
HMG-CoA reductase
Product does not compete with ATP.
Reversible: no
Warning
Toxicity: Standard Handling (A)
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 2 months at -20°C.
Other Notes
Sugiyama, M., et al. 2000. Biochem. Biophys. Res. Commun.271, 688.
Hug, T., et al. 1995. Pflugers Archiv. Eur. J. Physiol.429, 682.
Belo, R.S., et al. 1993. Mol.Cell. Biochem.126, 159.
McLeish, K.R., et al. 1993. Biochem. Biophys. Res. Commun.197, 763.
Keyomarsi, K., et al. 1991. Cancer Res. 51, 3602.
Jackson, J.H., et al. 1990. Proc. Natl. Acad. Sci. USA 87, 3042.
Kita, T., et al. 1980. J. Clin. Invest. 66, 1094.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
- UPC:
- 51182423
- Condition:
- New
- Availability:
- 3-5 Days
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- MPN:
- 474700-50MG
- CAS:
- 73573-88-3
